Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22389Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Sternberg, C. N. | en |
| dc.contributor.author | ten Bokkel Huinink, W. W. | en |
| dc.contributor.author | Smyth, J. F. | en |
| dc.contributor.author | Bruntsch, V. | en |
| dc.contributor.author | Dirix, L. Y. | en |
| dc.contributor.author | Pavlidis, N. A. | en |
| dc.contributor.author | Franklin, H. | en |
| dc.contributor.author | Wanders, S. | en |
| dc.contributor.author | Le Bail, N. | en |
| dc.contributor.author | Kaye, S. B. | en |
| dc.date.accessioned | 2015-11-24T19:23:56Z | - |
| dc.date.available | 2015-11-24T19:23:56Z | - |
| dc.identifier.issn | 0007-0920 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22389 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antineoplastic Agents, Phytogenic/*administration & dosage/adverse effects | en |
| dc.subject | Colorectal Neoplasms/*drug therapy | en |
| dc.subject | Dose-Response Relationship, Drug | en |
| dc.subject | Drug Administration Schedule | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Paclitaxel/administration & dosage/adverse effects/*analogs & derivatives | en |
| dc.subject | *Taxoids | en |
| dc.title | Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/7914427 | - |
| heal.identifier.secondary | http://www.nature.com/bjc/journal/v70/n2/pdf/bjc1994309a.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1994 | - |
| heal.abstract | Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-2 every 3 weeks as a 1 h infusion without routine premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range 41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: liver in 26 patients, lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma. | en |
| heal.journalName | Br J Cancer | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Sternberg-1994-Docetaxel (Taxotere).pdf | 697.86 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
